Loading market dashboard
Aadi Bioscience, Inc.
AADIHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Insider and Institutional Ownership 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money
Whitehawk Therapeutics CEO Dave Lennon outlined the company's strategy and near-term milestones at the Inaugural Life Sciences Conference in Miami, describing a three-program antibody-drug conjugate (ADC) pipeline built around a shared linker-payload system and focused on targets the company believes can support broad activity across multiple tumor types. Company reset and runway Lennon said the
